#India #financial results #Mumbai #Piramal Pharma #FY2025

Piramal Pharma Limited Announces Quarterly and Annual Results for FY2025

Piramal Pharma Limited, a prominent player in the global pharmaceutical and wellness sector, announced its financial results for the fourth quarter and the fiscal year ending March 31, 2025. The company's performance indicates robust growth, primarily fueled by its Contract Development and Manufacturing Organization (CDMO) segment.

Financial Highlights

For Q4 FY2025, Piramal Pharma achieved:

• - Total Revenue from Operations: ₹27.54 billion, a rise of 8% compared to ₹25.52 billion in Q4 FY2024.
• - Annual Revenue: Reached ₹91.51 billion, marking a 12% increase against ₹81.71 billion in FY2024.
• - EBITDA: Reported at ₹6.03 billion with a margin of 22%, showcasing an 8% rise from the previous year's quarter.
• - Profit After Tax (PAT): Increased significantly to ₹1.54 billion for Q4 FY2025, a 16% growth from ₹1.32 billion in the same period last year.

These results also highlight a substantial improvement in the company's financial ratios, with net debt to EBITDA improving to 2.7x from 5.6x in FY2023, reflecting enhanced operational efficiencies and cost-management strategies.

Segment Performance

Piramal's success is attributed to key product areas and strategic initiatives:

• - CDMO Sector: This segment was instrumental, contributing ₹17.88 billion in revenue for Q4 FY2025, an increase of 8% year-on-year. The company capitalized on growing demand for patented commercial production services, achieving over 50% growth in commercial manufacturing revenues compared to FY2024.
• - Complex Hospital Generics (CHG): This sector saw promising developments with significant contract renewals in inhalation anesthesia, maintaining a leading position in the U.S. market for Sevofluran with a 44% market share. The progress in the international markets also reflects the segment's expansion potential.
• - India Consumer Healthcare (ICH): The ICH business exceeded ₹10 billion in revenue, driven by a 20% growth in the Power Brands portfolio, which constituted 49% of total ICH revenue. Despite regulatory challenges impacting certain product lines, the growth trajectory remained strong with successful product launches helping to widen their market reach.

Strategic Outlook

Nandini Piramal, chairwoman of Piramal Pharma Limited, noted, “Fiscal year 2025 was a stable year for the company, where we achieved $1 billion in revenue with a growth of 12% compared to the previous year, alongside an EBITDA margin of 17%.” The company is optimistic about meeting its long-term growth goals, targeting $2 billion in revenues by FY2030 with an EBITDA margin improvement to 25%.

Moreover, investments in capabilities and technologies are expected to enhance product offerings while ensuring top-tier quality control, maintaining their 'Zero OAIs' status since 2011.

In conclusion, Piramal Pharma Limited's financial results for Q4 and FY2025 highlight the company's strong performance across various segments, setting a positive trajectory for continuous growth as it advances its strategic initiatives. Investors and stakeholders can look forward to the developments as Piramal aims for further innovation and market leadership in the pharmaceutical sector.